Glioblastoma (GBM) is a particularly devastating tumor with a median survival of about 16
months. Recent research has revealed novel insights into the outstanding heterogeneity of …

Background Patients suffering from malignant gliomas have a poor prognosis. For the
surgical treatment of these tumors, 5‐aminolevulinic acid (5‐ALA) has become a new …

Glioblastoma is an aggressive brain tumor that carries a poor prognosis. The tumor's
molecular and cellular landscapes are complex, and their relationships to histologic features …

Glioblastoma (GBM) is the most common and lethal type of malignant brain tumor in adults.
Currently, interventions are lacking, the median overall survival of patients with GBM is less …

Implantation of biodegradable wafers near the brain surgery site to deliver anti-cancer
agents which target residual tumor cells by bypassing the blood-brain barrier has been a …

Vessel co-option is a non-angiogenic mechanism of tumour vascularisation in which cancer
cells utilise pre-existing blood vessels instead of inducing new blood vessel formation …

Background Glioblastoma (GBM) is the most common and aggressive primary malignant
brain tumor. Leptomeningeal spread (LMS) is a severe complication of GBM, raising …

Simple Summary Bevacizumab mediated anti-angiogenesis provides a new chance of
survival for patients with a tumor. However, most patients have acquired bevacizumab …

The current work describes the development of a “nanopaper-based analytical device
(NAD)”, through the embedding of curcumin in transparent bacterial cellulose (BC) …

Triple‐negative breast cancer (TNBC) represents 10–20% of all human ductal
adenocarcinomas and has a poor prognosis relative to other subtypes, due to the high …